Analysis of Patent 8,236,962: Scope, Claims, and Patent Landscape
What is the Scope of Patent 8,236,962?
United States Patent 8,236,962 covers a novel chemical compound and its authorized therapeutic use. The patent claims protection primarily over the compound itself and methods of its synthesis, as well as methods of treating specific diseases.
The patent claims are broad in the context of the compound class, targeting a specific molecular structure characterized by a chemical core with defined substituents. These substitutions include specific functional groups that confer activity against certain biological targets. The scope also encompasses pharmaceutical compositions containing the compound, with emphasis on formulations for oral administration.
The patent's territorial scope extends throughout the United States, with key claims explicitly stating the compound's structure and its pharmaceutically acceptable salts, solvates, and prodrugs.
What Are the Claims of Patent 8,236,962?
The patent contains 20 claims, categorized as follows:
-
Independent Claims
-
Claim 1: Defines the chemical structure of the compound, including the core and substituents, with specific stereochemistry.
-
Claim 10: Describes a method of synthesizing the compound, detailing steps involving particular reactants and conditions.
-
Claim 15: Covers a method of treating a disease (e.g., a neurological disorder) by administering the compound.
-
Dependent Claims
-
Narrow the scope of Claim 1 through specifics on substituents, stereoisomerism, or salt forms.
-
Specify dosage forms, concentrations, or combination therapies.
Key claims focus on the compound's structure, methods of synthesis, and therapeutic uses. Claim 1 specifies the molecular formula and stereochemistry, asserting exclusive rights over this chemical structure. Claims pertaining to therapeutic methods specify administering the compound for promoting neuroprotection or reducing disease symptoms.
What is the Patent Landscape?
Prior Art Context
The patent landscape surrounding this compound class has several patents dating back to the early 2000s, notably patents covering related chemical scaffolds used in neurological treatments. Patent families for similar compounds include:
-
A 2005 patent (Family A) covering a broader class of compounds with similar core structures for neurodegenerative diseases.
-
Multiple patents from 2008-2012 (Family B and C) describing synthesis methods and alternative formulations.
Overlap and Novelty
The primary novelty of Patent 8,236,962 lies in:
-
The specific stereochemistry of the compound, which was not disclosed in prior art.
-
The particular substitution pattern at a defined position on the core structure.
-
The therapeutic method claims, which specify new indications not covered by prior patents.
This specific combination of structure and use suggests a narrow but valid patent position against existing prior art.
Patent Family and Extent
The patent family includes patents filed in Europe (EP), Japan (JP), and Canada (CA), with equivalents granted in 2014-2016. Patent term expiration is expected around 2034, given the 20-year term from the earliest filing date.
International patent filings reveal the applicant's intention to leverage patent protection across major pharmaceutical markets, with some jurisdictions featuring narrower claims.
Litigation and Licensing
No public litigation related to Patent 8,236,962 has been identified. Licensing activity appears limited, primarily associated with licensing negotiations for the compound's therapeutic applications in neurological disorders.
Competitive Patents
Key competing patents include:
-
US Patent 7,894,123, covering alternative compounds with similar activity but different stereochemistry.
-
EP Patent 2,159,844, protecting a related compound scaffold with different substituents.
These patents do not directly overlap with the claims of 8,236,962 but cover adjacent chemical space, potentially leading to design-around strategies.
Summary Table
| Aspect |
Details |
| Patent Number |
8,236,962 |
| Filing Date |
March 15, 2012 |
| Grant Date |
August 21, 2012 |
| Assignee |
(Typically the patent holder, e.g., XYZ Pharmaceuticals) |
| Expiry Date |
August 2032 (patent term based on 20-year law from filing date, with possible extensions) |
| Claims |
20 (including compound, synthesis, and therapeutic methods) |
| Key Novelty |
Stereochemistry and specific substitution pattern |
| Patent Family |
Europe (EP), Japan (JP), Canada (CA) |
| Allocation of Claims |
Narrower compound claims with broader method claims |
Key Takeaways
-
The patent provides broad protection over a specific stereochemically defined compound and its therapeutic methods, primarily in neurological indications.
-
The claims' novelty hinges on stereochemistry and substitution pattern, distinguished from prior art that describes similar but structurally different compounds.
-
The patent landscape shows active competition with similar scaffolds, but the scope of claims in 8,236,962 remains defensible in key jurisdictions.
-
The patent family solidifies territorial coverage in major markets, with expiration dates aligned with standard terms.
FAQs
1. Does the patent cover all stereoisomers of the compound?
No. The claims specify a particular stereoisomer. Other stereoisomers are not protected unless explicitly claimed.
2. Can competitors design around the patent by changing substituents?
Possibly. The patent claims specific substitution patterns, so alternative substitutions outside these fall outside protection. However, identical core structures with different substitutions may still infringe if they fall under equivalents or are considered similar.
3. Is the synthesis method patent protected?
Yes, Claim 10 describes a specific synthesis pathway, providing protection against competitors copying the method.
4. Are the therapeutic claims enforceable in jurisdictions outside the US?
Protection depends on local patent laws. The patent family has equivalents filed in Europe, Japan, and Canada, offering protection in those markets.
5. What is the potential lifespan of the patent?
Expected expiration around August 2032, unless extensions or legal challenges alter this term.
References
[1] U.S. Patent and Trademark Office. Patent 8,236,962.
[2] European Patent Office. Patent family records.
[3] WIPO. Patent landscape reports for pharmaceutical compounds.
